Compare VRA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | ENTX |
|---|---|---|
| Founded | 1982 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.6M | 147.4M |
| IPO Year | 2010 | 2015 |
| Metric | VRA | ENTX |
|---|---|---|
| Price | $5.81 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 500.6K | ★ 574.1K |
| Earning Date | 09-15-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $416,097,000.00 | $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.56 | N/A |
| P/E Ratio | ★ N/A | $11.45 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.39 | $0.91 |
| 52 Week High | $5.93 | $4.20 |
| Indicator | VRA | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 77.17 | 46.12 |
| Support Level | $2.99 | $1.46 |
| Resistance Level | N/A | $2.78 |
| Average True Range (ATR) | 0.33 | 0.17 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 95.38 | 36.28 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.